Patent · US Active

Method of assessing rheumatoid arthritis by measuring anti-CCP and anti-PIK3CD

US10094826B2 · kind B2 · utility

0Cited by

2References

8Claims

0Family size

Assignee

Roche Diagnostics Operations, Inc. · US

Inventors

Herbert Andres · Penzberg, DE
Stefan Weiser · Rosbach, DE
Johann Karl · Peißenberg, DE
Ursula Kunert · Munich, DE
Florian Grupp · Iffeldorf, DE

Key dates

Filing date	Aug 10, 2017
Grant date	Oct 9, 2018
Priority date	—
Expiry date	Aug 10, 2037

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/102
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

Described is a method aiding in the assessment of rheumatoid arthritis (“RA”). The method is used in assessing RA in vitro. It is practiced by analyzing biochemical markers, including measuring the concentration of anti-CCP and anti-PIK 3CD and correlating the concentrations determined to the absence or presence of RA. Also disclosed is the use of a marker panel including anti-CCP and anti-PIK3CD in the diagnosis of RA and it teaches a kit for performing the method. Also described is the use of a marker panel comprising anti-CCP and anti-PIK3CD to differentiate RA from other autoimmune diseases, preferably osteoarthritis (OA).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.